ASX:MSB Mesoblast (MSB) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10.19 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.58%Price TargetN/A Stock AnalysisStock Analysis Get Mesoblast alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Mesoblast Stock (ASX:MSB)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. MSB Stock News HeadlinesJuly 25 at 10:13 AM | sg.finance.yahoo.comLWB1.BE,0P0001JS8Q,0 (LWB1.BE)July 21, 2024 | finance.yahoo.comLWB1.SG,0P0001JSPL,0 (LWB1.SG)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 22, 2024 | msn.comIt’s horses for courses and April was ASX Resources: Selfwealth’s latest best ofMay 13, 2024 | msn.comInsider still buying Mesoblast shares despite 230% rise this year: Should you buy?May 2, 2024 | msn.com9 ASX All Ords shares elevated to 'strong buy' status in AprilApril 23, 2024 | fool.com.auIf you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!April 5, 2024 | msn.comWhy the Mesoblast share price can rise another 60%July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.March 28, 2024 | msn.comTop 5 Health Care Stocks That May Plunge In MarchMarch 27, 2024 | finance.yahoo.comAfter Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell TransplantMarch 26, 2024 | msn.comMesoblast gains as FDA backs regulatory plans for cell therapyMarch 15, 2024 | finance.yahoo.comMESO Mar 2024 3.000 putMarch 11, 2024 | msn.comWhy is the Mesoblast share price jumping 16% on Monday?March 11, 2024 | markets.businessinsider.comMesoblast : FDA Backs Accelerated Approval For Rexlemestrocel-L In Heart Failure PatientsMarch 7, 2024 | msn.comAustralia stocks higher at close of trade; S&P/ASX 200 up 0.39%February 17, 2024 | finance.yahoo.comMESO Mar 2024 2.000 putFebruary 4, 2024 | afr.comWhat investors can learn from analysing R&D spendingSee More Headlines Receive MSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolASX:MSB CUSIPN/A CIKN/A Webwww.mesoblast.com Phone+61-3-96396036FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth9.56Net Income$-73,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-14.49% Return on Assets-5.61% Debt Debt-to-Equity Ratio23.98 Current Ratio2.71 Quick Ratio1.82 Sales & Book Value Annual Sales$7.47 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow30.00 Book ValueA$0.50 per share Price / BookN/AMiscellaneous Outstanding Shares1,140,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.42 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $1.13MDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $956.61kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey Competitors(GTAX)OTCMKTS:GTAX(MACC.L)LON:MACC(SDM.AX)ASX:SDM177079 (IMN.TO)TSE:IMN26444 (ONL.L)LON:ONLView All CompetitorsInsidersPhilip KrauseSold 985,000 sharesTotal: $1.08 M ($1.10/share)Eric RoseBought 19,734 shares on 5/8/2024Total: $151,201.91 ($7.66/share)Eric RoseBought 21,428 shares on 4/30/2024Total: $142,324.78 ($6.64/share)Jane BellBought 233,918 shares on 4/12/2024Total: $199,999.89 ($0.86/share)Philip FacchinaSold 290,432 sharesTotal: $82,773.12 ($0.29/share) MSB Stock Analysis - Frequently Asked Questions How were Mesoblast's earnings last quarter? Mesoblast Limited (ASX:MSB) posted its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) earnings per share for the quarter. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Genfit (GNFT), Pluristem Therapeutics (PSTI) and Starpharma (SPL). This page (ASX:MSB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.